Cartesian Therapeutics Stock Buy Hold or Sell Recommendation

RNAC Stock   14.36  0.52  3.49%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cartesian Therapeutics is 'Strong Sell'. Macroaxis provides Cartesian Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding RNAC positions.
  
Check out Cartesian Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.
In addition, we conduct extensive research on individual companies such as Cartesian and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Cartesian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Execute Cartesian Therapeutics Buy or Sell Advice

The Cartesian recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cartesian Therapeutics. Macroaxis does not own or have any residual interests in Cartesian Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cartesian Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

3  Months

Risk Tolerance

I am an educated risk taker
Execute Advice
Sell Cartesian TherapeuticsBuy Cartesian Therapeutics
JavaScript chart by amCharts 3.21.15
Strong Sell

Market Performance

Very WeakDetails

Volatility

Not too volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Actively responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Not AvailableDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Cartesian Therapeutics has a Mean Deviation of 2.57, Standard Deviation of 3.37 and Variance of 11.36
Our trade advice tool can cross-verify current analyst consensus on Cartesian Therapeutics and to analyze the company potential to grow in the current economic cycle. To make sure Cartesian Therapeutics is not overpriced, please confirm all Cartesian Therapeutics fundamentals, including its book value per share, beta, and the relationship between the net income and earnings per share . Given that Cartesian Therapeutics has a shares owned by institutions of 26.66 %, we suggest you to validate Cartesian Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Cartesian Therapeutics Trading Alerts and Improvement Suggestions

Cartesian Therapeutics generated a negative expected return over the last 90 days
Cartesian Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (5.99 M).
Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations.
Cartesian Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 59.0% of the company outstanding shares are owned by corporate insiders

Cartesian Therapeutics Returns Distribution Density

The distribution of Cartesian Therapeutics' historical returns is an attempt to chart the uncertainty of Cartesian Therapeutics' future price movements. The chart of the probability distribution of Cartesian Therapeutics daily returns describes the distribution of returns around its average expected value. We use Cartesian Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cartesian Therapeutics returns is essential to provide solid investment advice for Cartesian Therapeutics.
Mean Return
-0.38
Value At Risk
-5.48
Potential Upside
4.63
Standard Deviation
3.37
   Return Density   
JavaScript chart by amCharts 3.21.15-18.94-14.15-9.35-4.8-0.243.958.3613.017.6422.28VARUpside 0.0050.0100.0150.0200.0250.0300.035
JavaScript chart by amCharts 3.21.15GOOGLE
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cartesian Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Cartesian Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cartesian Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cartesian Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cartesian stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.41
β
Beta against Dow Jones-0.74
σ
Overall volatility
3.37
Ir
Information ratio -0.11

Cartesian Therapeutics Volatility Alert

Cartesian Therapeutics exhibits very low volatility with skewness of -0.06 and kurtosis of 0.26. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cartesian Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cartesian Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Cartesian Therapeutics Fundamentals Vs Peers

Comparing Cartesian Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cartesian Therapeutics' direct or indirect competition across all of the common fundamentals between Cartesian Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cartesian Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cartesian Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cartesian Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Cartesian Therapeutics to competition
FundamentalsCartesian TherapeuticsPeer Average
Return On Equity-70.29-0.31
Return On Asset-0.06-0.14
Profit Margin(1.99) %(1.27) %
Operating Margin25.23 %(5.51) %
Current Valuation186.87 M16.62 B
Shares Outstanding25.91 M571.82 M
Shares Owned By Insiders59.28 %10.09 %
Shares Owned By Institutions26.66 %39.21 %
Number Of Shares Shorted2.02 M4.71 M
Price To Book31.26 X9.51 X
Price To Sales9.91 X11.42 X
Revenue38.91 M9.43 B
Gross Profit(5.99 M)27.38 B
EBITDA(75.99 M)3.9 B
Net Income(77.42 M)570.98 M
Cash And Equivalents106.44 M2.7 B
Total Debt13.98 M5.32 B
Book Value Per Share(0.26) X1.93 K
Cash Flow From Operations(23.67 M)971.22 M
Short Ratio25.39 X4.00 X
Earnings Per Share(4.49) X3.12 X
Target Price37.33
Number Of Employees6618.84 K
Beta0.83-0.15
Market Capitalization385.5 M19.03 B
Total Asset435.02 M29.47 B
Retained Earnings(692.07 M)9.33 B
Working Capital193.65 M1.48 B
Net Asset435.02 M
Note: Acquisition by Springer Timothy A of 54889 shares of Cartesian Therapeutics at 15.5877 subject to Rule 16b-3 [view details]

Cartesian Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cartesian . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Cartesian Therapeutics Buy or Sell Advice

When is the right time to buy or sell Cartesian Therapeutics? Buying financial instruments such as Cartesian Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Cartesian Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Baby Boomer Prospects Thematic Idea Now

Baby Boomer Prospects
Baby Boomer Prospects Theme
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 73 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:
Check out Cartesian Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.